|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ablation of T cell-derived IL-10 increased the IFN-γ and IL-17A response to HDM, reducing IL-13 levels and airway eosinophilia without affecting IgE levels or airway hyperresponsiveness.
|
31445933 |
2020 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
CLCA1 mRNA and periostin protein, previously identified biomarkers of IL-13-mediated epithelial activation, were elevated in columnar epithelial cell-high sputum samples, but only when accompanied by eosinophilia.
|
31264263 |
2019 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, we provide direct in vivo evidence that induced expression of IL-18 in the enterocytes promotes eotaxin-1, IL-5 and IL-13 independent intestinal eosinophilia, which signifies the clinical relevance of induced IL-18 in eosinophil-associated gastrointestinal disorders (EGIDs) to food allergens.
|
30779114 |
2019 |
|
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Discovered DMRs annotated to genes implicated in allergic asthma, Th2 activation and eosinophilia (EPX, IL4, IL13) and genes previously associated with asthma and IgE in EWAS of blood (ACOT7, SLC25A25).
|
31300640 |
2019 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Allergens such as house dust mites (HDM) and papain induce strong Th2 responses, including elevated IL-4, IL-5, and IL-13 and marked eosinophilia in the airways.
|
30348735 |
2018 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
These medications target the type 2 inflammatory pathway, which is characterized by activation of cytokines, including interleukin (IL)-4, IL-5, and IL-13, which results in eosinophilia, high FeNO, and atopic features.
|
30056149 |
2018 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PJE treatment inhibited OVA-induced inflammatory cell infiltration, eosinophilia, Th2 activation, and GATA-3 expression in the lung, reduced the interleukin (IL)-5 and IL-13 levels in BALF, down-regulated Th2 activation in vitro, and inhibited the macrophage production of inducible nitric oxide, cyclooxygenase-2, tumor necrosis factor-α, and IL-6.
|
28919220 |
2018 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma.
|
29319845 |
2018 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Eosinophilic bronchitis is usually a Type 2 (T2)-driven process and therefore a sputum eosinophilia of greater than 3% usually indicates a response to treatment with corticosteroids or novel therapies directed against T2 cytokines such as IL-4, IL-5, and IL-13.
|
29018800 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-5 induced eosinophilia only, but IL-13 contributed to both nasal epithelial thickening and eosinophilia induced by OVA-plus-papain.
|
28541554 |
2017 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-13 levels are elevated in animal models of eosinophilic inflammation and in the blood and tissue of patients diagnosed with eosinophilic disorders.
|
29034234 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
We report that T<sub>H</sub>2 cells express high levels of PPAR-γ in response to the allergen house dust mite and after infection with the parasite <i>Heligmosomoides polygyrus</i> Mice lacking PPAR-γ in T cells failed to effectively differentiate into IL-5- and IL-13-secreting cells and, hence, did not develop T<sub>H</sub>2 cell-associated pathologies, including goblet cell metaplasia and eosinophilia, in response to allergen challenge.
|
28783701 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, a significant proportion of this IL-13 epigenetic signature was validated in freshly isolated AECs from subjects with asthma and clustered into two distinct modules, with module 1 correlated with asthma severity and lung function and module 2 with eosinophilia.
|
26474238 |
2016 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
New therapies in the form of humanized antibodies against Th2 targets, such as anti-IgE, anti-IL4Rα, anti-IL-5 and anti-IL-13 antibodies, have shown encouraging results in terms of reduction in exacerbations and improvement in airflow in patients with a 'Th2-high' expression profile and blood eosinophilia.
|
26076339 |
2016 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Esophageal LRRC31 mRNA and protein increased in active EoE and strongly correlated with esophageal eosinophilia and IL13 and CCL26 (chemokine (C-C motif) ligand 26) mRNA expression.
|
26462420 |
2016 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-33-induced eosinophilia was ablated in IL-13 null mice.
|
26514775 |
2016 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Type 2 innate lymphoid cells (ILC2s) are a newly identified subset of immune cells that, along with Th2 cells, contribute to the pathogenesis of asthma by producing copious amounts of IL-5 and IL-13, which cause eosinophilia and airway hyperreactivity (AHR), a cardinal feature of asthma.
|
25769613 |
2015 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
By combining the expression levels of IL-4, IL-5, and IL-13 in a single quantitative metric ("T(H)2 gene mean"), 26 (70%) of the 37 asthmatic patients had T(H)2-high asthma, which was characterized by more severe measures of asthma and increased blood and sputum eosinophilia.
|
24075231 |
2014 |
|
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Similarly, we found that esophageal eosinophilia in IL-4/IL-13 double gene-deficient and STAT6 gene-deficient mice were also not reduced following allergen-induced experimental EoE.
|
23689305 |
2013 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-13-induced esophageal eosinophilia was dependent on eotaxin-1 (but not eotaxin-2).
|
20543112 |
2010 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Animal studies using IL-13 deficient mice, IL-13 transgenic animals, and IL-13 neutralization strategies have confirmed an essential role for this cytokine in driving major correlates of asthma pathology, including airway hyperresponsiveness (AHR), lung eosinophilia, mucus generation, and fibrosis.
|
18502398 |
2008 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
After intranasal allergen exposures, a modest decrease in bronchoalveolar lavage fluid eosinophilia and IL-13 levels was observed in Sftpd-/- mice compared with values seen in wild-type mice in association with decreased airway resistance (P < .01).
|
18355911 |
2008 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In particular, IL-13 mediates allergen-induced eotaxin-2 expression, and eotaxin-2 mediates IL-13-induced airway eosinophilia.
|
15647285 |
2005 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that secreted vvGs uses mechanisms requiring signaling through the IL-4Ralpha-chain by either IL-4 or IL-13 for induction of eosinophilia and is the first description of the relative contributions of IL-4, IL-13, and their receptors in viral pathogenesis.
|
12574374 |
2003 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
In animal models of allergic asthma, blockade of IL-13 markedly inhibits allergen-induced AHR, mucus production and eosinophilia.
|
12091879 |
2002 |